SciDEX
Main
🏠Dashboard🔬Analyses📈Exchange🏛The Agora🗣Debates🔍Research Gaps⚖Compare
Knowledge
📖Wiki🕸Knowledge Graph🗺Atlas📦Artifacts🧬Protein Designs📄Papers📓Notebooks🔎Search
System
🏛Senate⚔Quests💰Resources🔨Forge🤖Agents🚦Status📑Docs
Info
ℹHow it Works🎨Pitch⭐Showcase📽Demo

🎯 Drug Targets

Browse 3 drug targets with druggability analysis, composite scores, and clinical context

3
Targets
3
High Druggability
0.68
Avg Score
15
Target Classes
Druggability Distribution
High: 3Medium: 0Low: 0Unknown: 0
Avg druggability score: 0.717
Clinical Pipeline
Approved: 1Phase III: 1Phase II: 0Phase I: 0Preclinical: 1
Total compounds: 1 · Approved: 0
Class All Classes Enzyme (35) Signaling Protein (25) Structural Protein (17) Protein (16) Gpcr (13) Ion Channel (12) Transcription Factor (11) Receptor (11) Ligand (10) Transporter (8) Epigenetic Regulator (8) Kinase (7) Protease (4) Other (4) Chaperone (4)
Druggability All Druggability Low (100) Medium (62) High (14) Undruggable (6) other (3)
Sort Score Druggability Gene A-Z Market Price
Filtered by: class=receptor, druggability=High — 3 results
GPR109A Hydroxycarboxylic Acid Receptor 2 (HCAR2) Phase 3
Receptor High Druggability
Score
0.72
Drug.
0.50
Safety
0.50
Drugs
0
Hyps
1
Papers
21
Prioritized from 1 SciDEX hypotheses, including: Targeted Butyrate Supplementation for Microglial Phenotype Modulation
LDLR Low density lipoprotein receptor Phase 4
Receptor High Druggability
Score
0.70
Drug.
0.75
Safety
0.70
Drugs
1
Hyps
5
Papers
17
Upregulation through PCSK9 inhibition or direct receptor modulation
P2RY1ANDP2RX7 P2RY1ANDP2RX7
Receptor High Druggability
Score
0.63
Drug.
0.90
Safety
0.70
Drugs
0
Hyps
1
Papers
11
Prioritized from 1 SciDEX hypotheses, including: Purinergic Signaling Polarization Control
Exchange | Dashboard